EFS-Web Receipt date: 04/26/2005

bondence is being deposited with the U.S. Postal I hereby certify that thi No. EV492345757US, in an envelope addressed Service as Express Ma to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 26, 2005

Signature: Susar M Dullon (Susan Dillon)

JC Rec'd PCT/PTO 26 APR

Docket No.: 62807(46701)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Armin Breitenbach et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For:

TRANSDERMAL DELIVERY OF (R)-3,3-

Examiner: Not Yet Assigned

DIPHENYLPROPYLAMIN-MONOESTERN

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

EFS-Web Receipt date: 04/26/2005

10753856859: 1621

 2

Docket No.: 62807(46701)

JC14 Rec'd PCT/PTO 2 6 APR 2005

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62807(46701). A duplicate copy of this paper is enclosed.

By

Dated: April 26, 2005

Respectfully submitted

Peter F. Corless

Registration No.: 33,860 EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorney for Applicant

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e it contains a valid OMR o

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are requ

(Use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number Not Yet Assigned				
Filing Date	Concurrently Herewith			
First Named Inventor	or Armin Breitenbach			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	62807(46701)			

U.S. PATENT DOCUMENTS					
Examiner Cite No.1	Cita	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,638,528-B1	10-28-2003	Kanios	
	AB	US-6,555,129-B1	04-29-2003	Arth et al.	
	AC	US-2004/0081683-A1	04-29-2004	Schacht et al.	
	AD	US-2003/0157156-A1	08-21-2003	Hsu et al.	
	ΑE	US-2002/0147236-A1	10-10-2002	Sanders et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ⁶		
	ВА	EP-0 957 073-A1	11-17-1999	Schwarz Pharma AG				
	BB	WO-01/35957-A1	05-25-2001	Schwarz Pharma				
	BC	WO-99/58478-A1	11-18-1999	Schwarz Pharma AG		$ \mathbf{V} $		
	BD	WO-2004/089872-A1	10-21-2004	Schwarz Pharma AG				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Emperor must precede the serial number of the patent document. Kind of document the serial number of the patent document. by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant is to place a check mark here if English language

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Chukwuma Nwaonicha/	Date	02/28/2008
Signature	- Original Person Control Cont	Considered	02/26/2008

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.